These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9039062)

  • 1. Reference-based pricing of prescription drugs.
    McLaughlin PR
    Can J Cardiol; 1997 Jan; 13(1):31-2. PubMed ID: 9039062
    [No Abstract]   [Full Text] [Related]  

  • 2. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

  • 3. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 4. Coverage of drug costs: reference-based pricing.
    McGregor M
    Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference-based pricing (RBP) of prescription drugs.
    Holbrook A; O'Brien B; Grootendorst P
    Can J Cardiol; 1997 Jul; 13(7):689-90. PubMed ID: 9251582
    [No Abstract]   [Full Text] [Related]  

  • 6. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
    Boulet AP; Tessier G
    Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The change of cost: reference-based pricing and the statins.
    Thomas M
    Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662
    [No Abstract]   [Full Text] [Related]  

  • 9. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
    Shantsila A; Lip GY
    Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004
    [No Abstract]   [Full Text] [Related]  

  • 10. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
    Margolis RE
    Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
    [No Abstract]   [Full Text] [Related]  

  • 11. [The computerised prescription in Primary Care and its impact on drug spending using time series analysis].
    Catalán-Arlandis JL
    Rev Calid Asist; 2011; 26(1):18-27. PubMed ID: 21334242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
    McNee W
    Can J Cardiol; 1999 Nov; 15(11):1287. PubMed ID: 10841625
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rationale for the pharmacologic treatment of cardiovascular diseases].
    Perdigão C
    Rev Port Cardiol; 1998 May; 17(5):453-61. PubMed ID: 9656768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. President's page: evaluation and management--the 51% solution.
    Lewis RP
    J Am Coll Cardiol; 1997 Jan; 29(1):219-20. PubMed ID: 8996318
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescription pricing across Canada (Part II).
    Archer F
    CPJ; 1984 Sep; 117(9):434-5. PubMed ID: 10268225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Past the wall in cardiovascular R&D.
    Topol EJ
    Nat Rev Drug Discov; 2009 Apr; 8(4):259. PubMed ID: 19348004
    [No Abstract]   [Full Text] [Related]  

  • 18. [Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
    Wehling M
    Dtsch Med Wochenschr; 2004 Feb; 129(7):330. PubMed ID: 14765334
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating reference-based pricing: initial findings and prospects.
    Narine L; Senathirajah M; Smith T
    CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.